pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects

"Peritoneal carcinomatosis is a serious concern in the treatment of abdominal tumors such as hepatic, gastric and gynecological tumors", says Dr. Oliveira. "The strategy of local chemotherapy is interesting due to the possibility to increase the therapeutic efficacy while minimizing systemic side-effects. SpHL-CDDP treatment was able to reduce cancer cell proliferation and increase survival, in the animal model, with no known toxicity clinical signs found in the free CDDP treatment." says Dr. Maroni.

These results open the possibility of future use of SpHL-CDDP in chemotherapy of peritoneal carcinomatosis. "New studies are underway in our research group to investigate the signaling pathways of cell death as well as use of high doses of SpHL-CDDP for the treatment of peritoneal carcinomatosis", says Dr. Teixeira-Carvalho.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said " This very interesting study has utilized a new pH-sensitive circulating liposome containing cisplatin formulation which decreased cancer proliferation and drug toxicity in a mouse model. This provides the basis for further translational testing of this formulation leading to clinical trials aimed at more effective treatment of abdominal tumors".

Journal reference: Experimental Biology and Medicine

Provided by Society for Experimental Biology and Medicine